Memphasys

Memphasys Current Liabilities

The Current Liabilities of Memphasys (MEM.AX) as of Oct 18, 2026 is 7.02 M AUD. In the previous year, Current Liabilities was 10.31 M AUD — a change of -31.89% (lower).

Current Liabilities

7.02 MAUD

YoY

-31.89%

Last updated:

Current Liabilities of Memphasys is 2026 7.02 M AUD. Current Liabilities of Memphasys was 2025 10.31 M AUD. It decreases by -31.89% lower compared to the previous year.

The Memphasys Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
740,224.00 AUD
Jan 1, 2020
696,397.00 AUD
Jan 1, 2021
934,639.00 AUD
Jan 1, 2022
7.98 M AUD
Jan 1, 2023
10.10 M AUD
Jan 1, 2024
9.61 M AUD
Jan 1, 2025
10.31 M AUD
Jan 1, 2026
7.02 M AUD
The Memphasys Current Liabilities history
YEARCurrent LiabilitiesYoY
7.02 MAUD-31.89%
10.31 MAUD+7.28%
9.61 MAUD-4.89%
10.10 MAUD+26.62%
7.98 MAUD+753.43%
934,639.00AUD+34.21%
696,397.00AUD-5.92%
740,224.00AUD-58.27%
1.77 MAUD-90.20%
18.10 MAUD+18.22%
15.31 MAUD+169.97%
5.67 MAUD+150.14%
2.27 MAUD-45.35%
4.15 MAUD-22.78%
5.37 MAUD+71.49%
3.13 MAUD+23.69%
2.53 MAUD-65.91%
7.43 MAUD+95.72%
3.80 MAUD+68.98%
2.25 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

Current Liabilities of Memphasys is 7.02 M AUD in 2026.

Current Liabilities of Memphasys changed from 10.31 M AUD to 7.02 M AUD, representing a -31.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Memphasys since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Memphasys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Memphasys

All Key Metrics — Memphasys